Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:RXRXNASDAQ:SDGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeRXRXRecursion Pharmaceuticals$4.20-0.9%$7.17$3.80▼$12.36$1.69B111.05 million shs25.00 million shsSDGRSchrödinger$18.21+1.0%$22.62$16.60▼$29.15$1.33B1.77770,095 shs1.22 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceRXRXRecursion Pharmaceuticals-0.94%-20.60%-36.27%-43.93%-52.65%SDGRSchrödinger+1.00%-7.75%-13.37%-13.90%-32.36%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationRXRXRecursion Pharmaceuticals1.9416 of 5 stars3.22.00.00.02.02.50.6SDGRSchrödinger2.6746 of 5 stars3.52.00.00.03.82.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceRXRXRecursion Pharmaceuticals 2.40Hold$8.2596.43% UpsideSDGRSchrödinger 3.00Buy$32.2977.30% UpsideCurrent Analyst Ratings BreakdownLatest SDGR and RXRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/8/2025RXRXRecursion PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.002/28/2025RXRXRecursion PharmaceuticalsCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold2/28/2025RXRXRecursion PharmaceuticalsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Perform ➝ Market Perform$7.00 ➝ $6.002/27/2025SDGRSchrödingerPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$50.00 ➝ $45.002/6/2025RXRXRecursion PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.001/24/2025SDGRSchrödingerKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$25.00 ➝ $27.001/8/2025RXRXRecursion PharmaceuticalsKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$12.00 ➝ $10.00(Data available from 4/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookRXRXRecursion Pharmaceuticals$58.49M28.87N/AN/A$1.98 per share2.12SDGRSchrödinger$207.54M6.41$0.49 per share37.42$7.60 per share2.40Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateRXRXRecursion Pharmaceuticals-$328.07M-$1.66N/AN/AN/A-579.52%-76.56%-55.68%5/8/2025 (Estimated)SDGRSchrödinger$40.72M-$2.57N/AN/AN/A-91.84%-35.77%-24.51%4/29/2025 (Estimated)Latest SDGR and RXRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/29/2025N/ASDGRSchrödinger-$0.81N/AN/AN/A$54.60 millionN/A2/28/2025Q4 2024RXRXRecursion Pharmaceuticals-$0.36-$0.53-$0.17-$0.53$19.04 million$4.60 million2/26/2025Q4 2024SDGRSchrödinger-$0.35-$0.55-$0.20-$0.55$83.20 million$88.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthRXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/ASDGRSchrödingerN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioRXRXRecursion Pharmaceuticals0.044.354.35SDGRSchrödingerN/A4.114.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipRXRXRecursion Pharmaceuticals89.06%SDGRSchrödinger79.05%Insider OwnershipCompanyInsider OwnershipRXRXRecursion Pharmaceuticals15.75%SDGRSchrödinger8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableRXRXRecursion Pharmaceuticals400401.99 million329.18 millionOptionableSDGRSchrödinger79073.04 million66.59 millionOptionableSDGR and RXRX HeadlinesRecent News About These CompaniesSchrödinger, Inc. (NASDAQ:SDGR) Shares Purchased by Massachusetts Financial Services Co. MAApril 7 at 4:31 AM | marketbeat.comSchrödinger (NASDAQ:SDGR) Is In A Good Position To Deliver On Growth PlansMarch 27, 2025 | finance.yahoo.comSchrödinger, Inc. (NASDAQ:SDGR) Receives Consensus Recommendation of "Buy" from BrokeragesMarch 27, 2025 | marketbeat.comSchrödinger (NASDAQ:SDGR) Trading Down 4.5% - What's Next?March 26, 2025 | marketbeat.comSchrödinger to Present Preclinical Data at AACR Annual MeetingMarch 25, 2025 | finance.yahoo.comSchrödinger, Inc. (NASDAQ:SDGR) Position Boosted by AmundiMarch 21, 2025 | marketbeat.comSchrödinger (NASDAQ:SDGR) Shares Down 5.4% - What's Next?March 19, 2025 | marketbeat.comTejara Capital Ltd Trims Stake in Schrödinger, Inc. (NASDAQ:SDGR)March 19, 2025 | marketbeat.comNikko Asset Management Americas Inc. Boosts Stock Position in Schrödinger, Inc. (NASDAQ:SDGR)March 18, 2025 | marketbeat.comBank of New York Mellon Corp Sells 27,211 Shares of Schrödinger, Inc. (NASDAQ:SDGR)March 16, 2025 | marketbeat.com80,000 Shares in Schrödinger, Inc. (NASDAQ:SDGR) Acquired by Monaco Asset Management SAMMarch 15, 2025 | marketbeat.comSchrödinger (NASDAQ:SDGR) Trading Up 11.3% - Should You Buy?March 12, 2025 | marketbeat.comSchrödinger beruft Bridget van Kralingen in den VorstandMarch 10, 2025 | de.investing.comSchrödinger Expands Board of Directors with Appointment of Bridget van KralingenMarch 10, 2025 | finance.yahoo.comSchrödinger Expands Board of Directors with Appointment of Bridget van KralingenMarch 10, 2025 | businesswire.comSchrödinger: Still Waiting On A CatalystMarch 2, 2025 | seekingalpha.comSchrödinger, Inc. (SDGR) Q4 2024 Earnings Call TranscriptMarch 1, 2025 | seekingalpha.comSchrödinger, Inc. (SDGR) Q4 2024 Earnings Call TranscriptMarch 1, 2025 | seekingalpha.comSchrodinger price target lowered to $45 from $50 at Piper SandlerFebruary 27, 2025 | markets.businessinsider.comSchrödinger Reports Strong Fourth Quarter and Full-Year 2024 Financial ResultsFebruary 27, 2025 | finance.yahoo.comSchrodinger, Inc. (SDGR) Reports Q4 Loss, Tops Revenue EstimatesFebruary 26, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSDGR and RXRX Company DescriptionsRecursion Pharmaceuticals NASDAQ:RXRX$4.20 -0.04 (-0.94%) Closing price 04/7/2025 04:00 PM EasternExtended Trading$4.45 +0.25 (+5.93%) As of 09:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.Schrödinger NASDAQ:SDGR$18.21 +0.18 (+1.00%) Closing price 04/7/2025 04:00 PM EasternExtended Trading$19.40 +1.20 (+6.56%) As of 09:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Will CrowdStrike's Goodwill Strategy Pay Off in Revenue Gains? Options Activity Points to More Volatility for Palantir Stock NVIDIA Stock: Oversold, Undervalued — How Low Can It Go? MicroStrategy Sees Insider Buy-Sell Action in Q1 Buffett’s Next Oil Bet: Why Occidental Is Different Springing Dividends: 3 Dividend Boosters to Watch Now Alibaba Caught in Tariff Crossfire: Is It Time to Buy? Can Solid Biosciences Challenge Sarepta in the DMD Market? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
